紫杉醇脂质体与紫杉醇治疗非小细胞肺癌64例和乳腺癌62例的疗效

目的:比较紫杉醇脂质体与紫杉醇治疗非小细胞肺癌和乳腺癌的临床疗效和安全性。方法:本研究为多中心、开放、随机、对照研究。试验组和对照组分别静脉注射紫杉醇脂质体或紫杉醇135 mg·m~(-2),d 1给予,每3 wk重复一次,共2个疗程。非小细胞肺癌2组均联合顺铂75 mg·m~(-2),d 1给予,乳腺癌2组均联合表柔比星60 mg·m~(-2),d 1给予。结果:入组126例病人中,120例病人完成疗程,可评价疗效,非小细胞肺癌试验组有效率27％,对照组有效率17％。乳腺癌试验组有效率43％,对照组有效率37％,2组间疗效比较均无显著差异(P>0．05)。2组不良反应发生率无显著差异(P>0．05)。对照组3例(5％)系因Ⅲ度过敏反应而退出,试验组无过敏反应。结论:紫杉醇脂质体是治疗非小细胞肺癌和乳腺癌安全、有效的药物。

Effects of liposomal paclitaxel and paclitaxel in treatment of non-small-cell lung cancer (64 patients) and breast cancer (62 patients)

AIM: To analyze the efficacy and safety of liposomal paclitaxel in comparison with paclitaxel for patients with non-small-cell lung cancer and breast cancer. METHODS: Sixty-four patients with non-small-cell lung cancer were randomized to be treated with liposomal paclitaxel plus cisplatin or paclitaxel plus cis-platin. Sixty-two patients with breast cancer were randomized to be undertaken liposomal paclitaxel plus epiru-bicin or paclitaxel plus epirubicin therapy, response was evaluated after 2 courses of chemotherapy.The patients therapeutic course was discontinued when disease progressed. RESULTS: Of 126 patients,there were 120 eligible for the analysis of overall response rate and 126 for adverse reactions.Overall response rates of patients with non-small-cell lung cancer was 27 % for liposomal paclitaxel plus cisplatin group and 17 % for paclitaxel plus cisplatin group (P > 0.05). Overall response rate of patients with breast cancer was 43 % for liposomal paclitaxel plus epirubicin group and 37 % for paclitaxel plus epirubicin group (P > 0.05). There was no significant difference in serious adverse reactions between the two groups.There were three patients (5 %) treated with paclitaxel showed grade Ⅲ allergic reaction outcoming with discontinuation of the treatment. CONCLUSION: Liposomal paclitaxel is effective and safe for the treatment of non-small—cell lung cancer and breast cancer.